Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Long-term Outcomes for Me… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Long-term Outcomes for Men in a Prostate Screening Trial with an Initial Benign Prostate Biopsy: A Population-based Cohort

Artikel i vetenskaplig tidskrift
Författare Emmeli Palmstedt
Marianne Månsson
Maria Frånlund
Johan Stranne
Carl Gustaf Pihl
Jonas Hugosson
Rebecka Arnsrud Godtman
Publicerad i European Urology Oncology
Volym 2
Nummer/häfte 6
Sidor 716-722
ISSN 2588-9311
Publiceringsår 2019
Publicerad vid Institutionen för biomedicin
Institutionen för kliniska vetenskaper, Avdelningen för urologi
Sidor 716-722
Språk en
Länkar dx.doi.org/10.1016/j.euo.2019.01.01...
Ämnesord Benign biopsy, Mortality, Prostate-specific antigen, Prostate cancer, cancer, accuracy, Oncology, Urology & Nephrology
Ämneskategorier Urologi och njurmedicin, Cancer och onkologi

Sammanfattning

Background: The optimal follow-up regimen for men after a benign prostate biopsy remains unknown. Objective: To investigate long-term outcomes for men after an initial benign prostate biopsy. Design, setting, and participants: All men with a benign biopsy in the first screening round of the Goteborg prostate cancer (PC) screening trial were included. The follow-up period was January 1, 1995-May 15, 2017. Intervention: Prostate-specific antigen (PSA) tests were performed every second year (upper median age limit 69 yr). Men with PSA >= 3 ng/ml underwent prostate biopsy (sextant biopsy up to 2009). Outcome measurement and statistical analysis: The 20-yr cumulative PC incidence and PC mortality were calculated using the 1 minus Kaplan-Meier method. Results and limitations: Of 452 men with a benign biopsy and followed for a median of 21.1 yr, 169 were diagnosed with PC and five died from PC. The 20-yr cumulative PC incidence and PC mortality were 40.0% and 1.4%, respectively. The corresponding figures were 38.8% and 0.6% for men with initial PSA <= 10 ng/ml, and 64.4% and 21.4% for PSA >10 ng/ml. The proportion of men untreated at final follow-up was similar in the two PSA groups (22% vs 23%). The use of sextant biopsy for many years of the trial is a limitation. Conclusions: Men with an initial benign prostate biopsy run a very low risk of dying from PC when participating in a screening program. However, if followed for a long period, many men will be diagnosed and treated for PC. Low-intensity follow-up, as in the Goteborg trial, appears sufficient for men with PSA <= 10 ng/ml after a benign biopsy. Patient summary: This study shows that men who participate in a prostate cancer screening trial have a low risk of dying from prostate cancer if the first biopsy does not show cancer. (C) 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?